Category Archives: Investor state dispute

Jane Kelsey: Governments in denial of a world changing around them

Source: NZHerald | March 29, 2017 The visit of China’s Premier Le Keqiang to New Zealand should be the catalyst for a mature and nuanced discussion of our future relationship with the world’s rising hegemon, not simply, whether we can renegotiate … Continue reading

Posted in Investor state dispute, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Open Letter to Ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People

Open Letter to Ambassadors of RCEP negotiating countries  Member countries Must Consider the Impact of RCEP on Access to Medicines in Developing Countries  Don’t trade our lives away! We are writing to you on behalf of the Delhi Network of … Continue reading

Posted in Data Exclusivity, FTA, Investor state dispute, IPR Enforcement, LDC transition period, Regional Comprehensive Economic Partnership, TRIPS plus, UN General Assembly HLM | Leave a comment

The Aids revolution is why Asean, India and China must resist controls on generic drugs

South China Morning Post, October 10, 2016 Maria Guevara says affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia China is set … Continue reading

Posted in Investor state dispute, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

New Report by Health Action International, Public Citizen and Commons Network Reveals Danger of TTIP Locking Europe & US into Higher Drug Prices, Failed Pharma Innovation Model

October 3 2016 As EU and US officials meet in New York for the 15th round of TTIP negotiations, the report warns the EU and US to resist pressure from pharmaceutical corporations and avoid including an intellectual property (IP) chapter … Continue reading

Posted in Investor state dispute, IPR, Transatlantic Trade and Investment Partnership (TTIP), TRIPS plus, Uncategorized | Leave a comment

The Significance Of Uruguay’s Win Over Philip Morris International

By Alexandra Nightingale, Intellectual Property Watch| July 21, 2016 The tobacco industry’s global efforts to use bilateral and multilateral agreements to challenge the spread of tobacco control measures such as trademark-minimising plain packages were dealt a significant blow last week … Continue reading

Posted in FTA, Investor state dispute, Uncategorized | Leave a comment